PURPOSE OF REVIEW: To review recent clinical and epidemiological studies regarding the prevention, diagnosis, and treatment of trachoma. RECENT FINDINGS: Newer studies propose novel diagnostic tests that appear sensitive for the detection of ocular chlamydial infection. For example, recent studies with ribosomal RNA-based nucleic acid amplification tests (NAATs) have demonstrated improved sensitivities compared to DNA-based NAATs; and the progression of scarring has now been characterized with confocal microscopy. Immunologic studies have further explored the etiology of clinical sequelae, suggesting that chronic inflammation can lead to progressive scarring even in the absence of Chlamydia. Mass oral azithromycin distributions remain a mainstay of treatment; studies have assessed the appropriate frequency and duration of treatment programs. Current studies have also explored ancillary effects of azithromycin distribution on mortality and bacterial infections. SUMMARY: Trachoma programs have had remarkable success at reducing chlamydial infection and clinical signs of trachoma. Recent work suggests improved methods to monitor infection and scarring, and better ways to distribute treatment. Whereas studies continue to demonstrate reduction in infection in hyperendemic areas, more work is necessary to achieve elimination of this blinding disease.
PURPOSE OF REVIEW: To review recent clinical and epidemiological studies regarding the prevention, diagnosis, and treatment of trachoma. RECENT FINDINGS: Newer studies propose novel diagnostic tests that appear sensitive for the detection of ocular chlamydial infection. For example, recent studies with ribosomal RNA-based nucleic acid amplification tests (NAATs) have demonstrated improved sensitivities compared to DNA-based NAATs; and the progression of scarring has now been characterized with confocal microscopy. Immunologic studies have further explored the etiology of clinical sequelae, suggesting that chronic inflammation can lead to progressive scarring even in the absence of Chlamydia. Mass oral azithromycin distributions remain a mainstay of treatment; studies have assessed the appropriate frequency and duration of treatment programs. Current studies have also explored ancillary effects of azithromycin distribution on mortality and bacterial infections. SUMMARY:Trachoma programs have had remarkable success at reducing chlamydial infection and clinical signs of trachoma. Recent work suggests improved methods to monitor infection and scarring, and better ways to distribute treatment. Whereas studies continue to demonstrate reduction in infection in hyperendemic areas, more work is necessary to achieve elimination of this blinding disease.
Authors: Mariko Bird; Chandler R Dawson; Julius S Schachter; Yinghui Miao; Ahmed Shama; Ahmed Osman; Ahmad Bassem; Thomas M Lietman Journal: J Infect Dis Date: 2003-04-30 Impact factor: 5.226
Authors: Sheila K West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Allen Foster; Robin L Bailey; David C W Mabey Journal: Lancet Date: 2005-10-08 Impact factor: 79.321
Authors: Saul N Rajak; Esmael Habtamu; Helen A Weiss; Amir Bedri; Teshome Gebre; Asrat Genet; Peng T Khaw; Robin L Bailey; David C W Mabey; Clare E Gilbert; Paul M Emerson; Matthew J Burton Journal: Ophthalmology Date: 2011-10-05 Impact factor: 12.079
Authors: Emma M Harding-Esch; Martin J Holland; Jean-François Schémann; Sandra Molina; Isatou Sarr; Aura A Andreasen; Chrissy h Roberts; Ansumana Sillah; Boubacar Sarr; Edward F Harding; Tansy Edwards; Robin L Bailey; David C W Mabey Journal: PLoS Negl Trop Dis Date: 2011-08-02
Authors: Eric Pearlman; Yan Sun; Sanhita Roy; Mausita Karmakar; Amy G Hise; Loretta Szczotka-Flynn; Mahmoud Ghannoum; Holly R Chinnery; Paul G McMenamin; Arne Rietsch Journal: Int Rev Immunol Date: 2013-02 Impact factor: 5.311
Authors: Jennifer K Lee; Germán A Enciso; Daniela Boassa; Christopher N Chander; Tracy H Lou; Sean S Pairawan; Melody C Guo; Frederic Y M Wan; Mark H Ellisman; Christine Sütterlin; Ming Tan Journal: Nat Commun Date: 2018-01-03 Impact factor: 14.919
Authors: Thuy Doan; Armin Hinterwirth; Ahmed M Arzika; Sun Y Cotter; Kathryn J Ray; Kieran S O'Brien; Lina Zhong; Eric D Chow; Zhaoxia Zhou; Susie L Cummings; Dionna Fry; Catherine E Oldenburg; Lee Worden; Travis C Porco; Jeremy D Keenan; Thomas M Lietman Journal: Open Forum Infect Dis Date: 2018-07-24 Impact factor: 3.835